Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

The San Francisco 49ers had a dreadful season, but there were still some silver linings. Injuries decimated the 49ers' offense throughout the year, helping sink them from Super Bowl participants ...

In a significant industry move, Eli Lilly announced plans to acquire Scorpion Therapeutics' experimental cancer therapy, STX-478, for $2.5 billion. This acquisition aims to bolster Eli Lilly's cancer ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...

Lilly to Buy Scorpion’s PI3Kα Inhibitor for Breast Cancer Eli Lilly announced that it is buying private biotech Scorpion Therapeutics’ novel mutant-selective PI3Kα inhibitor, STX-478 ...